A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

Model-based Analysis of ChIP-Seq (MACS)

Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556

Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities

Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382

PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197

Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position

Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer

Moreno-Rodriguez, T., Monterde, B., González-Silva, L., Betancor-Fernández, I., Revilla, C., Agraz-Doblás, A., Freire, J., Marrón, P. I., Quevedo, L., Blanco, R. E., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01748-y · Cited by 43

Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution

Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 47

MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer

Yamashita, N., Morimoto, Y., Fushimi, A., Ahmad, R., Bhattacharya, A., Daimon, T., Haratake, N., Inoue, Y., Ishikawa, S., Yamamoto, M., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0772 · Cited by 39

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers

Strati, A. D., Adamopoulos, C., Kotsantis, I., Psyrri, A. K., Lianidou, E. S., & Papavassiliou, A. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031235 · Cited by 41

Rho‐associated protein kinase‐dependent moesin phosphorylation is required for PD‐L1 stabilization in breast cancer

Meng, F., Su, Y., & Xu, B. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12804 · Cited by 40

Cytokine-armed pyroptosis induces antitumor immunity against diverse types of tumors

Orehek, S., Ramuta, T. Ž., Lainšček, D., Malenšek, Š., Šala, M., Benčina, M., Jerala, R., & Hafner‐Bratkovič, I. (2024) · Nature Communications · doi:10.1038/s41467-024-55083-3 · Cited by 41

PBRM1 Regulates Stress Response in Epithelial Cells

Porter, E. G. P., Dhiman, A., Chowdhury, B., Carter, B. C., Lin, H., Stewart, J. C., Kazemian, M., Wendt, M. K., & Dykhuizen, E. C. (2019) · iScience · doi:10.1016/j.isci.2019.04.027 · Cited by 37

Heat-Triggered Remote Control of CRISPR-dCas9 for Tunable Transcriptional Modulation

Gamboa, L., Phung, E. V., Li, H., Meyers, J. P., Hart, A. C., Miller, I. C., & Kwong, G. A. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b01005 · Cited by 36

Pbrm1 Steers Mesenchymal Stromal Cell Osteolineage Differentiation by Integrating PBAF-Dependent Chromatin Remodeling and BMP/TGF-β Signaling

Sinha, S., Biswas, M., Chatterjee, S. S., Kumar, S., & Sengupta, A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107570 · Cited by 38

MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer

Hagiwara, M., Fushimi, A., Bhattacharya, A., Yamashita, N., Morimoto, Y., Oya, M., Withers, H. G., Hu, Q., Liu, T., Liu, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2029298 · Cited by 37

LUBAC-mediated linear ubiquitination: a crucial regulator of immune signaling

IWAI, K. (2021) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.97.007 · Cited by 37

Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications

Dreier, M. R., Walia, J., & de la Serna, I. L. (2024) · Epigenomes · doi:10.3390/epigenomes8010007 · Cited by 39

Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer

Liao, L., Liu, Z. Z., Langbein, L. E., Cai, W., Cho, E.-A., Na, J., Niu, X., Jiang, W., Zhong, Z., Cai, W. L., et al. (2018) · eLife · doi:10.7554/elife.37925 · Cited by 39

Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer

Bala, P., Singh, A. K., Kavadipula, P., Kotapalli, V., Sabarinathan, R., & Bashyam, M. D. (2020) · Oncogene · doi:10.1038/s41388-020-01537-z · Cited by 37

Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology

Xie, H., Appelt, J. W., & Jenkins, R. W. (2021) · Cancers · doi:10.3390/cancers13236052 · Cited by 41

Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury

Williamson, L. M., Rive, C. M., Francesco, D. D., Titmuss, E., Chun, H.-J. E., Brown, S. D., Milne, K., Pleasance, E., Lee, A. F., Yip, S. S. F., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00238-4 · Cited by 38

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges

Indini, A., Massi, D., Pirro, M., Roila, F., Grossi, F., Sahebkar, A., Glodde, N., Bald, T., & Mandalà, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.005 · Cited by 38

Epigenetic mechanisms of tumor resistance to immunotherapy

Arenas-Ramirez, N., Sahin, D., & Boyman, O. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2908-7 · Cited by 36

Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha

Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P., Zeng, Z., Wang, C., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 35

Resistance to immune checkpoint inhibitors in gastric cancer

Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 36

Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression

Xie, Z., Ikegami, T., Ago, Y., Okada, N., & Tachibana, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1734268 · Cited by 36

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions

Deng, Q., Lakra, P., Gou, P., Yang, H., Meydan, C., Teater, M. R., Chin, C. R., Zhang, W., Dinh, T., Hussein, U. K., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.011 · Cited by 37

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma

Guo, W., Ma, J., Guo, S., Wang, H., Wang, S., Shi, Q., Liu, L., Zhao, T., Yang, F., Chen, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001866 · Cited by 35

Epigenetic modulation of immunotherapy and implications in head and neck cancer

Zhou, L., Xu, N., Shibata, H., Saloura, V., & Uppaluri, R. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09944-0 · Cited by 36

Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity

Peng, L., Zhou, L., Li, H., Zhang, X., Su, L., Wang, K., Yang, M., Ma, X., Zhang, D., Xiang, S., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114003 · Cited by 34

High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM 1

Liao, L., Alicea‐Velázquez, N. L., Langbein, L. E., Niu, X., Cai, W., Cho, E., Zhang, M., Greer, C. B., Yan, Q., Cosgrove, M. S., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12434 · Cited by 34

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

Choueiri, T. K., Atkins, M. B., Bakouny, Z., Carlo, M. I., Drake, C. G., Jonasch, E. W., Kapur, P., Lewis, B., Linehan, W. M., Mitchell, M. J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa064 · Cited by 33

Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy

Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 36

Genome-guided discovery of cancer therapeutic targets

Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36

Big Data Approaches for Modeling Response and Resistance to Cancer Drugs

Jiang, P., Sellers, W. R., & Liu, X. S. (2018) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-080917-013350 · Cited by 32

The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma

Hagiwara, M., Fushimi, A., Matsumoto, K., & Oya, M. (2021) · European Urology · doi:10.1016/j.eururo.2021.09.024 · Cited by 33

PPP2R1A mutations portend improved survival after cancer immunotherapy

Dai, Y., Knisely, A. T., Yano, M., Dang, M., Hinchcliff, E., Lee, S., Welp, A. M., Chelvanambi, M., Lastrapes, M. J., Liu, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09203-8 · Cited by 32

SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors

Panwalkar, P., Pratt, D. W., Chung, C., Dang, D., Le, P., Martínez, D., Bayliss, J. M., Smith, K. S., Adam, M., Potter, S. S., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa004 · Cited by 32

Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing

Chory, E. J., Kirkland, J. G., Chang, C.-Y., D’Andrea, V. D., Gourisankar, S. P., Dykhuizen, E. C., & Crabtree, G. R. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00312 · Cited by 33

Genomics-guided pre-clinical development of cancer therapies

Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32

CRISPR screen in cancer: status quo and future perspectives.

He, C., Han, S., Chang, Y., Wu, M., Zhao, Y., Chen, C. Y., & Chu, X. (2021) · PubMed · Cited by 37

Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study

Anžič, N., Krasniqi, F., Eberhardt, A.-L., Tzankov, A., & Haslbauer, J. D. (2021) · Case Reports in Oncology · doi:10.1159/000515416 · Cited by 33

Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade

Paschen, A., Melero, I., & Ribas, A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070220-111016 · Cited by 32

Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms

McKenzie, B., & Valitutti, S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.12.003 · Cited by 33

Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer

Hagel, K. R., Arafeh, R., Gang, S., Arnoff, T. E., Larson, R. C., Doench, J. G., Mathewson, N. D., Wucherpfennig, K. W., Maus, M. V., & Hahn, W. C. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2245 · Cited by 34

An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation

Krotova, K. Y., Day, A., & Aslanidi, G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.001 · Cited by 31

Expression of PD-L1 in EBV-associated malignancies

Li, X., & Zhang, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107553 · Cited by 31

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0053 · Cited by 31

HOIP limits anti-tumor immunity by protecting against combined TNF and IFN-gamma-induced apoptosis

Freeman, A. J., Vervoort, S. J., Michie, J., Ramsbottom, K. M., Silke, J., Kearney, C. J., & Oliaro, J. (2021) · EMBO Reports · doi:10.15252/embr.202153391 · Cited by 31

RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity

Zhang, Z., Luo, L., Xing, C., Chen, Y., Xu, P., Mao, L., Zeng, L., Li, C., Ghosh, S., Manna, D. D., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00263-z · Cited by 31

Tumor immunology CRISPR screening: present, past, and future

Dong, M. B., Tang, K., Zhou, X., Zhou, J. J., & Chen, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.11.009 · Cited by 32

High-throughput methods for genome editing: the more the better

Huang, Y., Shang, M., Liu, T., & Wang, K. (2022) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiac017 · Cited by 32

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy

Krishnamurthy, N., Kato, S., Lippman, S. M., & Kurzrock, R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004669 · Cited by 31

MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping

Filipescu, D., Carcamo, S., Agarwal, A., Tung, N., Humblin, É., Goldberg, M. S., Vyas, N. S., Beaumont, K. G., Demircioğlu, D., Sridhar, S., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01208-7 · Cited by 32

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses

Friedman, C. F., Manning‐Geist, B. L., Zhou, Q. C., Soumerai, T. E., Holland, A., Paula, A. D. C., Green, H., Ozsoy, M. A., Iasonos, A. E., Hollmann, T. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02942-7 · Cited by 30

Tumor Milieu Controlled by RB Tumor Suppressor

Kitajima, S., Li, F., & Takahashi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072450 · Cited by 30

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade

Gu, S. S., Wang, X., Hu, X. S., Jiang, P., Li, Z., Traugh, N. C., Bu, X., Tang, Q., Wang, C., Zeng, Z., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02166-1 · Cited by 29

Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date

Tacconi, E. M., Tuthill, M. H., & Protheroe, A. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s174149 · Cited by 30

The BAF chromatin remodeling complexes: structure, function, and synthetic lethalities

Varga, J., Kube, M., Luck, K., & Schick, S. (2021) · Biochemical Society Transactions · doi:10.1042/bst20190960 · Cited by 31

Novel Mouse Models for Cancer Immunology

Connolly, K. A., Fitzgerald, B., Damo, M., & Joshi, N. S. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-105523 · Cited by 31

SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers

Wang, D., Wang, J., Zhou, D., Wu, Z., Liu, W., Chen, Y., Chen, G., & Zhang, J. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0813 · Cited by 32

RECQL4 Inhibits Radiation‐Induced Tumor Immune Awakening via Suppressing the cGAS‐STING Pathway in Hepatocellular Carcinoma

Hong, W., Zhang, Y., Wang, S., Li, Z., Zheng, D.-X., Hsu, S.-J., Zhou, J., Fan, J., Chen, Z., Xia, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202308009 · Cited by 31

CLEC16A in astrocytes promotes mitophagy and limits pathology in a multiple sclerosis mouse model

Kadowaki, A., Wheeler, M. A., Li, Z., Andersen, B. M., Lee, H., Illouz, T., Lee, J.-H., Ndayisaba, A., Zandee, S., Basu, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01875-9 · Cited by 30

Enhancer Dysfunction in 3D Genome and Disease

Xia, J., & Wei, G. (2019) · Cells · doi:10.3390/cells8101281 · Cited by 26

Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis

Shi, L. Z., & Bonner, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212295 · Cited by 28

miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma

Nguyen, M.-H. T., Luo, Y.-H., Li, A.-L., Tsai, J.-C., Wu, K., Chung, P., & Ma, N. J.-L. (2021) · Biomolecules · doi:10.3390/biom11111648 · Cited by 30

Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy

Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 31

Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses

Yan, J., Chen, Y., Patel, A. J., Warda, S., Lee, C. J., Nixon, B. G., Wong, E. W. P., Miranda-Román, M. A., Yang, N., Wang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153437 · Cited by 30

PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma

Yao, X., Hong, J. H., Nargund, A. M., Ng, M. S. W., Heng, H. L., Li, Z., Guan, P., Sugiura, M., Chu, P. L., Wang, L. C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01122-y · Cited by 29

Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence

Zhang, S., Lin, T., Xiong, X., Chen, C., Tan, P., & Wei, Q. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00857-z · Cited by 30

PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity

Djajawi, T. M., Pijpers, L., Srivaths, A., Chisanga, D., Chan, K. F., Hogg, S. J., Neil, L., Rivera, S., Bartoniček, N., Ellis, S. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113831 · Cited by 29

Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors

Berland, L., Gabr, Z., Chang, M., Ilié, M., Hofman, V., Rignol, G., Ghiringhelli, F., Mograbi, B., Rashidian, M., & Hofman, P. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384121 · Cited by 31

OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy

Léon-Letelier, R. A., Bonifaz, L. C., & Fuentes‐Pananá, E. M. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0618-241rr · Cited by 30

Heat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1

Антонова, А. В., Hummel, B., Khavaran, A., Redhaber, D. M., Aprile-Garcia, F., Rawat, P., Gundel, K., Schneck, M., Hansen, E. C., Mitschke, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.084 · Cited by 27

Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management

Liu, Z., Liu, L., Lu, T., Wang, L., Li, Z., Jiao, D., & Han, X. (2021) · Journal of Oncology · doi:10.1155/2021/6664386 · Cited by 28

Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling

Shen, H., Huang, F., Zhang, X., Ojo, O. A., Li, Y., Trummell, H. Q., Anderson, J. C., Fiveash, J. B., Bredel, M., Yang, E. S.-H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32754-7 · Cited by 27

IFNγ is a central node of cancer immune equilibrium

Walsh, M. J., Stump, C. T., Kureshi, R., Lenehan, P. J., Ali, L. R., Dougan, M. L., Knipe, D. M., & Dougan, S. K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112219 · Cited by 28

(mis)-Targeting of SWI/SNF complex(es) in cancer

Reddy, D., Bhattacharya, S., & Workman, J. L. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10102-5 · Cited by 30

Mutual Regulation of ncRNAs and Chromatin Remodeling Complexes in Normal and Pathological Conditions

Bure, I. V., & Nemtsova, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097848 · Cited by 27

Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response

Tumuluru, S., Godfrey, J. K., Cooper, A. B., Yu, J., Chen, X., MacNabb, B. W., Venkataraman, G., Zha, Y., Pelzer, B. W., Song, J. Y., et al. (2025) · Blood · doi:10.1182/blood.2024025355 · Cited by 34

Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells

Hühn, D., Martí‐Rodrigo, P., Mouron, S. A., Hansel, C. S., Tschapalda, K., Porębski, B., Häggblad, M., Lidemalm, L., Quintela-Fandiño, M., Puigvert, J. C., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13083 · Cited by 34

Biochemistry, Pathophysiology, and Regulation of Linear Ubiquitination: Intricate Regulation by Coordinated Functions of the Associated Ligase and Deubiquitinase

Fuseya, Y., & Iwaï, K. (2021) · Cells · doi:10.3390/cells10102706 · Cited by 28

PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner

Zhou, M., Leung, J. Y., Gessner, K. H., Hepperla, A. J., Simon, J. M., Davis, I. J., & Kim, W. Y. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0480 · Cited by 26

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma

Cai, W., Nguyen, M. Q., Wilski, N. A., Purwin, T. J., Vernon, M., Tiago, M., & Aplin, A. E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3217 · Cited by 27

Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing

Liu, H., Zhao, R., Qin, R., Sun, H., Huang, Q., Liu, L., Tian, Z., Nashan, B., Sun, C., & Sun, R. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0050 · Cited by 27

High-throughput genetic screens using CRISPR–Cas9 system

Kweon, J., & Kim, Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1029-z · Cited by 27

Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional Chondrosarcoma

Li, B., Li, G., Yan, X., Zhu, D., Lin, P. P., Wang, Z., Qu, H., He, X., Fu, Y., Zhu, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1893 · Cited by 28

Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles

Zou, C., Liu, X., Wang, W., He, L., Yin, A., Cao, Z., Zhu, M., Wu, Y., Liu, X., Ma, J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03182-8 · Cited by 26

ARID2 Chromatin Remodeler in Hepatocellular Carcinoma

Loesch, R., Chenane, L., & Colnot, S. (2020) · Cells · doi:10.3390/cells9102152 · Cited by 26

Discovery and Validation of a Metastasis-Related Prognostic and Diagnostic Biomarker for Melanoma Based on Single Cell and Gene Expression Datasets

Wan, Q., Liu, C., Liu, C. X., Liu, W., Wang, X., & Wang, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.585980 · Cited by 27

Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need

Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 26

Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy

Chen, J., Chen, C., Zhan, Y., Zhou, L., Chen, J., Cai, Q., Wu, Y., Sui, Z., Zeng, C., Wei, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4521 · Cited by 29

BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer

Zhao, R., Liu, Y., Wu, C., Li, M., Wei, Y., Niu, W., Yang, J., Fan, S., Xie, Y., Li, H., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.659392 · Cited by 26

Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus

Colli, L. M., Jessop, L., Myers, T. A., Camp, S. Y., Machiela, M. J., Choi, J., Cunha, R., Onabajo, O. O., Mills, G. C., Schmid, V., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.07.009 · Cited by 27

Greek Fire, Poison Arrows, and Scorpion Bombs: How Tumor Cells Defend Against the Siege Weapons of Cytotoxic T Lymphocytes

McKenzie, B., Khazen, R., & Valitutti, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894306 · Cited by 27

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

Chen, J., Zuo, Z., Gao, Y., Yao, X., Guan, P., Wang, Y., Li, Z., Liu, Z., Hong, J. H., Deng, P., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01436-6 · Cited by 26

RFX6 facilitates aerobic glycolysis‐mediated growth and metastasis of hepatocellular carcinoma through targeting PGAM1

Qiu, Z., Wang, C., Huang, P., Yuan, Y., Shi, Y., Lin, Z., Huang, Z., Zuo, D., Qiu, J., He, W. A., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1511 · Cited by 26

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

Hariharan, S., Whitfield, B. T., Pirozzi, C. J., Waitkus, M. S., Brown, M. C., Bowie, M. L., Irvin, D., Roso, K., Fuller, R., Hostettler, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44932-w · Cited by 30

Extracellular matrix modulates T cell clearance of malignant cells in vitro

Robertson, C., Sebastian, A., Hinckley, A., Rios‐Arce, N. D., Hynes, W. F., Edwards, S. A., He, W., Hum, N. R., Wheeler, E. K., Loots, G. G., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121378 · Cited by 27

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Deutsch, J. S., Lipson, E. J., Danilova, L., Topalian, S. L., Jedrych, J. J., Baraban, E. G., Ged, Y. M. A., Singla, N., Choueiri, T. K., Gupta, S. K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100947 · Cited by 25

Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer

Jalalvand, M., Darbeheshti, F., & Rezaei, N. (2021) · Immunotherapy · doi:10.2217/imt-2020-0283 · Cited by 26

BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway

Prosdocimi, E., Carpanese, V., Todesca, L. M., Varanita, T., Bachmann, M., Festa, M., Bonesso, D., Pérez-Verdaguer, M., Carrer, A., Velle, A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn9361 · Cited by 25

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistance

Sreevalsan, S., Döring, M., Paszkowski‐Rogacz, M., Brux, M., Blanck, C., Meyer, M., Momburg, F., Buchholz, F., & Theis, M. (2020) · EMBO Reports · doi:10.15252/embr.202050155 · Cited by 26

Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis

Wang, N., Qin, Y., Du, F., Wang, X., & Song, C. (2022) · Gene · doi:10.1016/j.gene.2022.146638 · Cited by 24

Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma

Hong, W.-F., Liu, M.-Y., Liang, L., Zhang, Y., Li, Z., Han, K.-Q., Du, S., Chen, Y., & Ma, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868480 · Cited by 25

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249

Abstract 1599: SMARCA4 regulates tumor resistance to anti-tumor immune response

Chaudhri, A., Wang, Y., Shi, L., Rai, K., & Hwu, P. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1599

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 21

Abstract A146: Systematic discovery of immune regulatory mechanisms in tumor cells

Pan, D., Kobayashi, A., Jiang, P., Yuan, G., Liu, X. S., Doench, J. G., Qiu, X., Rao, P. K., Long, H. W., Brown, M. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr18-a146

SNF'ing out antitumor immunity

Kiberstis, P. A. (2018) · Science · doi:10.1126/science.359.6377.756-c